Clinical Scorecard: Effectiveness and Safety of PARP Inhibitors in Elderly Patients with Advanced Ovarian Cancer: A Systematic Review and Network Meta-Analysis

At a Glance

Key Highlights

• PARP inhibitors improved progression-free survival (PFS) in older patients (≥65 years).
• Olaparib, rucaparib, and niraparib showed significant PFS benefits compared to placebo or chemotherapy.
• Niraparib was associated with increased odds of treatment-emergent adverse events.
• Both niraparib and olaparib had higher risks of grade ≥3 anaemia and other hematologic toxicities.
• Placebo or chemotherapy ranked most favourably across most safety outcomes.

Guideline-Based Recommendations

Diagnosis

• Diagnosis of advanced ovarian cancer should consider age as a key risk factor.

Management

• PARP inhibitors can be used as maintenance therapy after platinum-based chemotherapy.

Monitoring & Follow-up

• Monitor for hematologic adverse events and gastrointestinal symptoms in older patients.

Risks

• Increased risk of treatment-emergent adverse events and hematologic toxicities in older adults.

Patient & Prescribing Data

Adults aged ≥18 years, including older adults (≥65 years) with advanced ovarian cancer.

Evidence suggests that older patients may experience similar efficacy from PARP inhibitors as younger patients, but with increased toxicity.

Clinical Best Practices

• Consider individual patient factors such as comorbidities and functional status when prescribing PARP inhibitors.
• Conduct age-stratified analyses to inform treatment decisions for older patients.

Related Resources & Content

• Systematic Review and Network Meta-Analysis